Sugi Predict

Sugi Predict / Compounds / SCHEMBL282566

SCHEMBL282566

SCHEMBL282566

CCc1nc(C(N)=O)c(Cl)nc1Cl

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ POLB P06746 1/20 0.35
▸ GABRP O00591 1/20 0.33
▸ GABRD O14764 1/20 0.33
▸ GABRA1 P14867 1/20 0.33
▸ GABRB1 P18505 1/20 0.33
▸ GABRG2 P18507 1/20 0.33
▸ GABRB3 P28472 1/20 0.33
▸ GABRA5 P31644 1/20 0.33
▸ GABRA3 P34903 1/20 0.33
▸ GABRA2 P47869 1/20 0.33
▸ GABRB2 P47870 1/20 0.33
▸ GABRA4 P48169 1/20 0.33
▸ GABRE P78334 1/20 0.33
▸ GABRA6 Q16445 1/20 0.33
▸ GABRG1 Q8N1C3 1/20 0.33
▸ GABRG3 Q99928 1/20 0.33
▸ GABRQ Q9UN88 1/20 0.33
▸ LMNA P02545 3/20 0.32
▸ PDPK1 O15530 1/20 0.31
▸ CDK8 P49336 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29452887 1.00 POLB (0.35) POLBGABRPGABRDGABRA1GABRB1
SCHEMBL25808946 0.82 TDP1 (0.38) GABRPGABRDGABRA1GABRB1GABRG2
SCHEMBL25808958 0.82 GABRP (0.31) GABRPGABRDGABRA1GABRB1GABRG2
SCHEMBL28083263 0.78 TDP1 (0.40) POLBLMNAPDPK1MAPTGAA
SCHEMBL29944853 0.77 NPSR1 (0.48) GABRPGABRDGABRA1GABRB1GABRG2
SCHEMBL25808937 0.77 NPSR1 (0.48) GABRPGABRDGABRA1GABRB1GABRG2
SCHEMBL25808963 0.77 SMN1; SMN2 (0.36) LMNAMAPTL3MBTL1GAAKMT2A
SCHEMBL25808782 0.77 CRHR1 (0.33) CYP1A2CYP2D6TSHRSLC9A1OPRM1
SCHEMBL25809135 0.75 POLB (0.41) POLBLMNAPDPK1GAADGAT1
SCHEMBL25562756 0.72 PLAU (0.37) POLBLMNAPDPK1GAAIKBKB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-112062728-A Synthetic method of 3, 5-dichloro-6-ethylpyrazine formamide 上海鑫凯化学科技有限公司 2020-12-11 — — CN claimed
US-20250312335-A1 FLT COMBINATION THERAPY FOR CANCER AND COMPOSITIONS THEREFOR BIOMEA FUSION, INC. 2025-10-09 — — US disclosed
US-20250136558-A1 PYRAZINE COMPOUNDS AS IRREVERSIBLE INHIBITORS OF FLT3 BIOMEA FUSION, INC. 2025-05-01 — — US disclosed
EP-4525873-A1 FLT3 COMBINATION THERAPY FOR CANCER AND COMPOSITIONS THEREFOR Biomea Fusion, Inc. (US) 2025-03-26 — — EP disclosed
US-20240262795-A1 PYRAZINE COMPOUNDS AS INHIBITORS OF FLT3 BIOMEA FUSION, INC. 2024-08-08 — — US disclosed
EP-4392409-A1 PYRAZINE COMPOUNDS AS IRREVERSIBLE INHIBITORS OF FLT3 Biomea Fusion, Inc. (US) 2024-07-03 — — EP disclosed
EP-4370506-A1 PYRAZINE COMPOUNDS AS INHIBITORS OF FLT3 Biomea Fusion, Inc. (US) 2024-05-22 — — EP disclosed
US-11945785-B2 Pyrazine compounds as inhibitors of FLT3 BIOMEA FUSION, INC. (US) 2024-04-02 — — US disclosed
WO-2023225005-A1 FLT3 COMBINATION THERAPY FOR CANCER AND COMPOSITIONS THEREFOR BIOMEA FUSION, INC. (US) 2023-11-23 — — WO disclosed
WO-2023225005-A1 FLT3 COMBINATION THERAPY FOR CANCER AND COMPOSITIONS THEREFOR BIOMEA FUSION, INC. (US) 2023-11-23 — — WO disclosed
EP-2428508-B1 DIAMINO HETEROCYCLIC CARBOXAMIDE COMPOUND ASTELLAS PHARMA INC (JP) 2015-12-16 — — EP disclosed
US-9085540-B2 Pyrazinecarboxamide compound ASTELLAS PHARMA INC. (JP) 2015-07-21 — — US disclosed
US-8969336-B2 Diamino heterocyclic carboxamide compound ASTELLAS PHARMA INC. (JP) 2015-03-03 — — US disclosed
US-20140371196-A1 DIAMINO HETEROCYCLIC CARBOXAMIDE COMPOUND ASTELLAS PHARMA INC. (JP) 2014-12-18 — — US disclosed
EP-2805940-A1 PYRAZINE CARBOXAMIDE COMPOUND Astellas Pharma Inc. (JP) 2014-11-26 — — EP disclosed
US-20140323463-A1 PYRAZINECARBOXAMIDE COMPOUND ASTELLAS PHARMA INC. (JP) 2014-10-30 — — US disclosed
CN-104080774-A Pyrazine carboxamide compound ASTELLAS PHARMA INC 2014-10-01 — — CN disclosed
CN-102421761-B Diamino heterocyclic carboxamide compound ASTELLAS PHARMA INC 2014-06-18 — — CN disclosed
EP-2428508-A1 DIAMINO HETEROCYCLIC CARBOXAMIDE COMPOUND Astellas Pharma Inc. (JP) 2012-03-14 — — EP disclosed
US-20120040968-A1 DIAMINO HETEROCYCLIC CARBOXAMIDE COMPOUND WATERS TECHNOLOGIES CORPORATION (US) 2012-02-16 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240262795-A1 PYRAZINE COMPOUNDS AS INHIBITORS OF FLT3 FLT3, MCL1, CSF3R POLB 1489/4885GABRP 2472/4885GABRD 3128/4885
US-20250136558-A1 PYRAZINE COMPOUNDS AS IRREVERSIBLE INHIBITORS OF FLT3 FLT3, MCL1, JAK2 POLB 1379/4885GABRP 2417/4885GABRD 3568/4885
US-20140371196-A1 DIAMINO HETEROCYCLIC CARBOXAMIDE COMPOUND EML4, ALK, ERBB4 POLB 4590/4885GABRP 3786/4885GABRD 3784/4885
US-11945785-B2 Pyrazine compounds as inhibitors of FLT3 FLT3, MCL1, JAK2 POLB 1028/4885GABRP 1841/4885GABRD 2977/4885
US-20140323463-A1 PYRAZINECARBOXAMIDE COMPOUND EGFR, ERBB2, ALK POLB 4018/4885GABRP 3140/4885GABRD 4316/4885
US-20120040968-A1 DIAMINO HETEROCYCLIC CARBOXAMIDE COMPOUND EML4, ALK, ERBB4 POLB 4590/4885GABRP 3786/4885GABRD 3784/4885
US-20250312335-A1 FLT COMBINATION THERAPY FOR CANCER AND COMPOSITIONS THEREFOR FLT3, MEN1, FEM1B POLB 666/4885GABRP 2862/4885GABRD 3372/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.